Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2020 | Nov. 02, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | DiaMedica Therapeutics Inc. | |
Entity Central Index Key | 0001401040 | |
Trading Symbol | dmac | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | No | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 18,739,074 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false | |
Title of 12(b) Security | Voting common shares, no par value per share |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 9,797 | $ 3,883 |
Marketable securities | 20,826 | 3,995 |
Amounts receivable | 335 | 823 |
Prepaid expenses and other assets | 138 | 47 |
Deposits | 10 | 88 |
Total current assets | 31,106 | 8,836 |
Non-current assets: | ||
Operating lease right-of-use asset | 114 | 153 |
Property and equipment, net | 50 | 64 |
Total non-current assets | 164 | 217 |
Total assets | 31,270 | 9,053 |
Current liabilities: | ||
Accounts payable | 720 | 182 |
Accrued liabilities | 658 | 1,076 |
Finance lease obligation | 6 | 6 |
Operating lease obligation | 59 | 54 |
Total current liabilities | 1,443 | 1,318 |
Non-current liabilities: | ||
Finance lease obligation, non-current | 8 | 13 |
Operating lease obligation, non-current | 61 | 105 |
Total non-current liabilities | 69 | 118 |
Shareholders’ equity: | ||
Common shares, no par value; unlimited authorized; 18,739,074 and 12,006,874 shares issued and outstanding, as of September 30, 2020 and December 31, 2019, respectively | ||
Paid-in capital | 94,457 | 64,232 |
Accumulated other comprehensive income | 10 | 2 |
Accumulated deficit | (64,709) | (56,617) |
Total shareholders’ equity | 29,758 | 7,617 |
Total liabilities and shareholders’ equity | $ 31,270 | $ 9,053 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Common shares, par value (in dollars per share) | $ 0 | $ 0 |
Common shares, authorized | Unlimited | Unlimited |
Common shares, issued (in shares) | 18,739,074 | 12,006,874 |
Common shares, outstanding (in shares) | 18,739,074 | 12,006,874 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Operating expenses: | ||||
Research and development | $ 2,180 | $ 1,617 | $ 5,190 | $ 6,098 |
General and administrative | 1,139 | 1,044 | 3,241 | 2,725 |
Operating loss | (3,319) | (2,661) | (8,431) | (8,823) |
Other (income) expense: | ||||
Governmental assistance - research incentives | (25) | (263) | (205) | (663) |
Other (income) expense, net | (103) | 38 | (154) | (20) |
Total other income | (128) | (225) | (359) | (683) |
Loss before income tax expense | (3,191) | (2,436) | (8,072) | (8,140) |
Income tax expense | 2 | 12 | 20 | 29 |
Net loss | (3,193) | (2,448) | (8,092) | (8,169) |
Other comprehensive income | ||||
Unrealized gain (loss) on marketable securities | (19) | (5) | 8 | 6 |
Net loss and comprehensive loss | $ (3,212) | $ (2,453) | $ (8,084) | $ (8,163) |
Basic and diluted net loss per share (in dollars per share) | $ (0.19) | $ (0.20) | $ (0.55) | $ (0.68) |
Weighted average shares outstanding – basic and diluted (in shares) | 16,689,074 | 12,006,874 | 14,652,749 | 11,981,233 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 11,956,874 | ||||
Balance at Dec. 31, 2018 | $ 62,993 | $ (45,968) | $ 17,025 | ||
Share-based compensation expense | 130 | 130 | |||
Unrealized gain (loss) on marketable securities | 3 | 3 | |||
Net loss | (3,252) | (3,252) | |||
Balance (in shares) at Mar. 31, 2019 | 11,956,874 | ||||
Balance at Mar. 31, 2019 | 63,123 | 3 | (49,220) | 13,906 | |
Balance (in shares) at Dec. 31, 2018 | 11,956,874 | ||||
Balance at Dec. 31, 2018 | 62,993 | (45,968) | 17,025 | ||
Unrealized gain (loss) on marketable securities | 6 | ||||
Net loss | (8,169) | ||||
Balance (in shares) at Sep. 30, 2019 | 12,006,874 | ||||
Balance at Sep. 30, 2019 | 63,831 | 6 | (54,137) | 9,700 | |
Balance (in shares) at Mar. 31, 2019 | 11,956,874 | ||||
Balance at Mar. 31, 2019 | 63,123 | 3 | (49,220) | 13,906 | |
Exercise of common stock options (in shares) | 50,000 | ||||
Exercise of common stock options | 75 | 75 | |||
Share-based compensation expense | 182 | 182 | |||
Unrealized gain (loss) on marketable securities | 8 | 8 | |||
Net loss | (2,469) | (2,469) | |||
Balance (in shares) at Jun. 30, 2019 | 12,006,874 | ||||
Balance at Jun. 30, 2019 | 63,380 | 11 | (51,689) | 11,702 | |
Share-based compensation expense | 451 | 451 | |||
Unrealized gain (loss) on marketable securities | (5) | (5) | |||
Net loss | (2,448) | (2,448) | |||
Balance (in shares) at Sep. 30, 2019 | 12,006,874 | ||||
Balance at Sep. 30, 2019 | 63,831 | 6 | (54,137) | 9,700 | |
Balance (in shares) at Dec. 31, 2019 | 12,006,874 | ||||
Balance at Dec. 31, 2019 | 64,232 | 2 | (56,617) | 7,617 | |
Issuance of common shares net of offering costs (in shares) | 2,125,000 | ||||
Issuance of common shares net of offering costs | 7,682 | 7,682 | |||
Exercise of common stock options (in shares) | 7,200 | ||||
Exercise of common stock options | 16 | 16 | |||
Share-based compensation expense | 393 | 393 | |||
Unrealized gain (loss) on marketable securities | 40 | 40 | |||
Net loss | (2,425) | (2,425) | |||
Balance (in shares) at Mar. 31, 2020 | 14,139,074 | ||||
Balance at Mar. 31, 2020 | 72,323 | 42 | (59,042) | 13,323 | |
Balance (in shares) at Dec. 31, 2019 | 12,006,874 | ||||
Balance at Dec. 31, 2019 | 64,232 | 2 | (56,617) | 7,617 | |
Unrealized gain (loss) on marketable securities | 8 | ||||
Net loss | (8,092) | ||||
Balance (in shares) at Sep. 30, 2020 | 18,739,074 | ||||
Balance at Sep. 30, 2020 | 94,457 | 10 | (64,709) | 29,758 | |
Balance (in shares) at Mar. 31, 2020 | 14,139,074 | ||||
Balance at Mar. 31, 2020 | 72,323 | 42 | (59,042) | 13,323 | |
Share-based compensation expense | 436 | 436 | |||
Unrealized gain (loss) on marketable securities | (13) | (13) | |||
Net loss | (2,474) | (2,474) | |||
Balance (in shares) at Jun. 30, 2020 | 14,139,074 | ||||
Balance at Jun. 30, 2020 | 72,759 | 29 | (61,516) | 11,272 | |
Issuance of common shares net of offering costs (in shares) | 4,600,000 | ||||
Issuance of common shares net of offering costs | 21,190 | 21,190 | |||
Share-based compensation expense | 508 | 508 | |||
Unrealized gain (loss) on marketable securities | (19) | (19) | |||
Net loss | (3,193) | (3,193) | |||
Balance (in shares) at Sep. 30, 2020 | 18,739,074 | ||||
Balance at Sep. 30, 2020 | $ 94,457 | $ 10 | $ (64,709) | $ 29,758 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands | 3 Months Ended | |
Sep. 30, 2020 | Mar. 31, 2020 | |
Stock Issuance [Member] | ||
Offering costs | $ 1,800 | $ 819 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (8,092,000) | $ (8,169,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Share-based compensation | 1,337,000 | 763,000 |
Amortization of discount on marketable securities | (24,000) | (68,000) |
Non-cash lease expense | 39,000 | 36,000 |
Depreciation | 16,000 | 16,000 |
Changes in operating assets and liabilities: | ||
Amounts receivable | 488,000 | 116,000 |
Prepaid expenses | (91,000) | 280,000 |
Deposits | 78,000 | (39,000) |
Accounts payable | 538,000 | (171,000) |
Accrued liabilities | (458,000) | (1,000) |
Net cash used in operating activities | (6,169,000) | (7,237,000) |
Cash flows from investing activities: | ||
Purchase of marketable securities | (25,048,000) | (10,928,000) |
Maturities of marketable securities | 8,249,000 | 6,000,000 |
Purchase of property and equipment | (2,000) | |
Disposition of property and equipment, net | 12,000 | |
Net cash used in investing activities | (16,801,000) | (4,916,000) |
Cash flows from financing activities: | ||
Proceeds from issuance of common shares, net of offering costs | 28,872,000 | |
Proceeds from the exercise of stock options | 16,000 | 75,000 |
Principal payments on finance lease obligations | (4,000) | (4,000) |
Net cash provided by financing activities | 28,884,000 | 71,000 |
Net increase (decrease) in cash and cash equivalents | 5,914,000 | (12,082,000) |
Cash and cash equivalents at beginning of period | 3,883,000 | 16,823,000 |
Cash and cash equivalents at end of period | $ 9,797,000 | $ 4,741,000 |
Note 1 - Business
Note 1 - Business | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1. Business DiaMedica Therapeutics Inc. and its wholly-owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively we, us, our, DiaMedica and the Company), exist for the primary purpose of advancing the clinical and commercial development of a proprietary recombinant, or synthetic, tissue Kallikrein- 1 KLK1 |
Note 2 - Risks and Uncertaintie
Note 2 - Risks and Uncertainties | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Risks and Uncertainties [Text Block] | 2. Risks and Uncertainties DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the FDA in the United States, the European Medicines Agency (EMA) in the European Union and comparable agencies in other countries. We are in the clinical stage of development of our initial product candidate, DM199, not not DM199 not three five Additionally, clinical testing is currently being adversely impacted by the novel strain of the coronavirus (COVID- 19 19 The Company's future success is dependent upon the success of its development efforts, its ability to demonstrate clinical progress for its DM199 DM199 As of September 30, 2020, $64.7 2000. nine September 30, 2020, $8.1 $6.2 DM199 September 30, 2020, $9.8 $20.8 $29.7 $29.8 no not We expect that we will need substantial additional capital to further our research and development activities, complete the required clinical trials and regulatory activities and otherwise develop our product candidate, DM199, may three twelve may no not may |
Note 3 - Summary of Significant
Note 3 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. Summary of Significant Accounting Policies Interim financial statements We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10 X not December 31. December 31, 2019 may not Cash and cash e quivalents The Company considers all bank deposits, including money market funds, and other investments, purchased with an original maturity to the Company of three Concentration of credit risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two not not Marketable securities The Company's marketable securities typically consist of obligations of the United States government and its agencies, investment grade corporate obligations and bank certificates of deposit, which are classified as available-for-sale and included in current assets as they are intended to fund current operations. Securities are valued based on market prices for similar assets using third Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may not not no September 30, 2020. Fair value measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three Level 1 Level 2 Level 3 As of September 30, 2020, 4, Marketable Securities |
Note 4 - Marketable Securities
Note 4 - Marketable Securities | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] | 4. Marketable Securities The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands): Fair Value Measurements Using Inputs Considered as of : September 30, 2020 December 31, 20 19 Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Government securities $ 12,827 $ — $ 12,827 $ — $ 1,998 $ — $ 1,998 $ — Bank certificates of deposit 1,748 — 1,748 — — — — — Commercial paper and corporate bonds 6,251 — 6,251 — 1,997 — 1,997 — Total $ 20,826 $ — $ 20,826 $ — $ 3,995 $ — $ 3,995 $ — Accrued interest receivable on available-for-sale securities is included in amounts receivable and was $38,000 $25,000 September 30, 2020 December 31, 2019, There were no 1 2 nine September 30, 2020. Under the terms of the Company's investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations and bank certificates of deposit with a primary objective of principal preservation. Maturities of individual securities are less than one September 30, 2020 December 31, 2019. |
Note 5 - Amounts Receivable
Note 5 - Amounts Receivable | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | 5. Amounts Receivable Amounts receivable consisted of the following (in thousands): September 30, 2020 December 31, 2019 Research and development incentives $ 289 $ 793 Accrued interest 38 17 Sales-based taxes receivable — 13 Other 8 — Total amounts receivable $ 335 $ 823 |
Note 6 - Deposits
Note 6 - Deposits | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Other Assets Disclosure [Text Block] | 6. Deposits Deposits consisted of the following (in thousands): September 30, 2020 December 31, 2019 Advances to vendors - current $ 10 $ 88 We periodically advance funds to vendors engaged to support the performance of our clinical trials and supporting activities. The funds advanced are held, interest free, for varying periods of time and may |
Note 7 - Property and Equipment
Note 7 - Property and Equipment | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 7. Property and Equipment Property and equipment consisted of the following (in thousands): September 30, 2020 December 31, 2019 Furniture and equipment $ 51 $ 51 Computer equipment 58 56 109 107 Less accumulated depreciation (59 ) (43 ) Property and equipment, net $ 50 $ 64 |
Note 8 - Accrued Liabilities
Note 8 - Accrued Liabilities | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 8. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): September 30, 2020 December 31, 201 9 Accrued compensation $ 340 $ 419 Accrued clinical study costs 211 433 Accrued research and other professional fees 94 172 Accrued taxes and other liabilities 13 52 Total accrued liabilities $ 658 $ 1,076 |
Note 9 - Operating Lease
Note 9 - Operating Lease | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 9. Operating Lease We lease certain office space under a non-cancelable operating lease. This lease does not not August 31, 2022 not This lease does not 9%, Our operating lease cost and variable lease costs were $49,000 $40,000, nine September 30, 2020. Maturities of our operating lease obligation are as follows as of September 30, 2020 ( 2020 $ 17 2021 68 2022 46 Total lease payments $ 131 Less interest portion (11 ) Present value of lease obligation $ 120 |
Note 10 - Shareholders' Equity
Note 10 - Shareholders' Equity | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 1 0 . Shareholders' Equity Authorized capital stock The Company has authorized share capital of an unlimited number of voting common shares and the shares do not Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one Equity issued during the nine ended September 30, 2020 On August 10, 2020, 4,600,000 $5.00 $23.0 $21.2 On February 13, 2020, 2,125,000 $4.00 $8.5 $7.7 On September 11, 2020, 10,000 $4.00 October 1, 2024, During the nine September 30, 2020, 7,200 $16,000 no Equity issued during the nine ended September 30 , 2019 During the nine September 30, 2019, 50,000 $75,000 no Shares reserved Common shares reserved for future issuance are as follows: September 30, 2020 Stock options outstanding 1,395,399 Deferred share units outstanding 47,237 Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan 1,107,431 Common shares issuable under common share purchase warrants 265,000 Total 2,815,067 |
Note 11 - Net Loss Per Share
Note 11 - Net Loss Per Share | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 1 1 . Net Loss Per Share We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive. The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data): Three Months Ended September 30, Nine M onths Ended September 30, 2020 2019 2020 2019 Net loss $ (3,193 ) $ (2,448 ) $ (8,092 ) $ (8,169 ) Weighted average shares outstanding—basic and diluted 16,689,074 12,006,874 14,652,749 11,981,233 Basic and diluted net loss per share $ (0.19 ) $ (0.20 ) $ (0.55 ) $ (0.68 ) The following outstanding potential common shares were not not Three Months Ended September 30, Nine M onths Ended September 30, 2020 201 9 2020 201 9 Employee and non-employee stock options 1,395,399 1,251,893 1,395,399 1,251,893 Common shares issuable under common share purchase warrants 265,000 807,563 265,000 807,563 Common shares issuable under deferred unit awards 47,237 21,183 47,237 21,183 |
Note 12 - Share-based Compensat
Note 12 - Share-based Compensation | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 12. Share-Based Compensation 2019 The DiaMedica Therapeutics Inc. 2019 2019 March 2019 May 22, 2019. 2019 2019 no ten one three five one 2019 2019 2,000,000 September 30, 2020, 866,515 26,054 2019 Prior stock option plan The DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated November 6, 2018 ( 2019 2019 September 30, 2020, 528,884 As the TSX Venture Exchange was the principal trading market for the Company's common shares, all options granted prior to December 31, 2018 December 31, 2018 Prior deferred share unit plan The DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan (DSU Plan) was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 September 30, 2020, 21,183 The aggregate number of common shares reserved for issuance for awards granted under the 2019 September 30, 2020 1,442,636. Share-based compensation expense for each of the periods presented is as follows (in thousands): Three Months Ended September 30 Nine Months Ended September 30 2020 2019 2020 2019 Research and development $ 141 $ 151 $ 379 $ 276 General and administrative 367 300 958 487 Total share-based compensation $ 508 $ 451 $ 1,337 $ 763 We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest. A summary of option activity is as follows (in thousands except share and per share amounts): Shares Underlying Options Outstanding Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balances at December 31, 2019 1,220,359 $ 5.32 $ — Granted 282,332 4.77 Exercised (7,200 ) 2.25 Expired/cancelled (78,147 ) 5.10 Forfeited (21,945 ) — Balances at September 30, 2020 1,395,399 $ 5.24 $ 301 Information about stock options outstanding, vested and expected to vest as of September 30, 2020, Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Weighted Average Options Weighted Average Contractual Life (Years) $2.00 - $2.99 125,700 5.3 $ 2.28 125,700 5.2 $3.00 - $3.99 97,905 6.2 3.88 97,905 6.2 $4.00 - $4.99 932,744 8.7 4.56 483,716 8.4 $5.00 - $10.00 188,900 7.0 7.84 130,280 7.2 $10.01 - $34.00 50,150 2.1 18.16 50,150 2.1 1,395,399 7.8 $ 5.24 887,751 7.2 |
Note 13 - Related Party Transac
Note 13 - Related Party Transaction | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 13. Related Party Transaction During 2020, no $90,000 $137,000 three nine September 30, 2020, $11,000 September 30, 2020. |
Note 14 - Commitments and Conti
Note 14 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 14. Commitments and Contingencies Litigation funding agreement On December 27, 2019, $1.0 not not September 21, 2020, not |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Interim financial statements We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10 X not December 31. December 31, 2019 may not |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and cash e quivalents The Company considers all bank deposits, including money market funds, and other investments, purchased with an original maturity to the Company of three |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of credit risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two not not |
Marketable Securities, Policy [Policy Text Block] | Marketable securities The Company's marketable securities typically consist of obligations of the United States government and its agencies, investment grade corporate obligations and bank certificates of deposit, which are classified as available-for-sale and included in current assets as they are intended to fund current operations. Securities are valued based on market prices for similar assets using third Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may not not no September 30, 2020. |
Fair Value Measurement, Policy [Policy Text Block] | Fair value measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three Level 1 Level 2 Level 3 As of September 30, 2020, 4, Marketable Securities |
Note 4 - Marketable Securities
Note 4 - Marketable Securities (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block] | Fair Value Measurements Using Inputs Considered as of : September 30, 2020 December 31, 20 19 Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Government securities $ 12,827 $ — $ 12,827 $ — $ 1,998 $ — $ 1,998 $ — Bank certificates of deposit 1,748 — 1,748 — — — — — Commercial paper and corporate bonds 6,251 — 6,251 — 1,997 — 1,997 — Total $ 20,826 $ — $ 20,826 $ — $ 3,995 $ — $ 3,995 $ — |
Note 5 - Amounts Receivable (Ta
Note 5 - Amounts Receivable (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] | September 30, 2020 December 31, 2019 Research and development incentives $ 289 $ 793 Accrued interest 38 17 Sales-based taxes receivable — 13 Other 8 — Total amounts receivable $ 335 $ 823 |
Note 6 - Deposits (Tables)
Note 6 - Deposits (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] | September 30, 2020 December 31, 2019 Advances to vendors - current $ 10 $ 88 |
Note 7 - Property and Equipme_2
Note 7 - Property and Equipment (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | September 30, 2020 December 31, 2019 Furniture and equipment $ 51 $ 51 Computer equipment 58 56 109 107 Less accumulated depreciation (59 ) (43 ) Property and equipment, net $ 50 $ 64 |
Note 8 - Accrued Liabilities (T
Note 8 - Accrued Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | September 30, 2020 December 31, 201 9 Accrued compensation $ 340 $ 419 Accrued clinical study costs 211 433 Accrued research and other professional fees 94 172 Accrued taxes and other liabilities 13 52 Total accrued liabilities $ 658 $ 1,076 |
Note 9 - Operating Lease (Table
Note 9 - Operating Lease (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | 2020 $ 17 2021 68 2022 46 Total lease payments $ 131 Less interest portion (11 ) Present value of lease obligation $ 120 |
Note 10 - Shareholders' Equity
Note 10 - Shareholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Common Stock Reserved for Future Issuance [Table Text Block] | September 30, 2020 Stock options outstanding 1,395,399 Deferred share units outstanding 47,237 Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan 1,107,431 Common shares issuable under common share purchase warrants 265,000 Total 2,815,067 |
Note 11 - Net Loss Per Share (T
Note 11 - Net Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended September 30, Nine M onths Ended September 30, 2020 2019 2020 2019 Net loss $ (3,193 ) $ (2,448 ) $ (8,092 ) $ (8,169 ) Weighted average shares outstanding—basic and diluted 16,689,074 12,006,874 14,652,749 11,981,233 Basic and diluted net loss per share $ (0.19 ) $ (0.20 ) $ (0.55 ) $ (0.68 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended September 30, Nine M onths Ended September 30, 2020 201 9 2020 201 9 Employee and non-employee stock options 1,395,399 1,251,893 1,395,399 1,251,893 Common shares issuable under common share purchase warrants 265,000 807,563 265,000 807,563 Common shares issuable under deferred unit awards 47,237 21,183 47,237 21,183 |
Note 12 - Share-based Compens_2
Note 12 - Share-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended September 30 Nine Months Ended September 30 2020 2019 2020 2019 Research and development $ 141 $ 151 $ 379 $ 276 General and administrative 367 300 958 487 Total share-based compensation $ 508 $ 451 $ 1,337 $ 763 |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Shares Underlying Options Outstanding Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balances at December 31, 2019 1,220,359 $ 5.32 $ — Granted 282,332 4.77 Exercised (7,200 ) 2.25 Expired/cancelled (78,147 ) 5.10 Forfeited (21,945 ) — Balances at September 30, 2020 1,395,399 $ 5.24 $ 301 |
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Weighted Average Options Weighted Average Contractual Life (Years) $2.00 - $2.99 125,700 5.3 $ 2.28 125,700 5.2 $3.00 - $3.99 97,905 6.2 3.88 97,905 6.2 $4.00 - $4.99 932,744 8.7 4.56 483,716 8.4 $5.00 - $10.00 188,900 7.0 7.84 130,280 7.2 $10.01 - $34.00 50,150 2.1 18.16 50,150 2.1 1,395,399 7.8 $ 5.24 887,751 7.2 |
Note 2 - Risks and Uncertaint_2
Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||||
Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (64,709) | $ (64,709) | $ (56,617) | |||||||
Net Income (Loss) Attributable to Parent, Total | (3,193) | $ (2,474) | $ (2,425) | $ (2,448) | $ (2,469) | $ (3,252) | (8,092) | $ (8,169) | ||
Net Cash Provided by (Used in) Operating Activities, Total | (6,169) | (7,237) | ||||||||
Cash, Cash Equivalents, and Short-term Investments, Total | 9,800 | 9,800 | ||||||||
Marketable Securities, Total | 20,800 | 20,800 | ||||||||
Working Capital | 29,700 | 29,700 | ||||||||
Stockholders' Equity Attributable to Parent, Ending Balance | $ 29,758 | $ 11,272 | $ 13,323 | $ 9,700 | $ 11,702 | $ 13,906 | $ 29,758 | $ 9,700 | $ 7,617 | $ 17,025 |
Note 4 - Marketable Securitie_2
Note 4 - Marketable Securities (Details Textual) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Accrued Interest Receivable On Available For Sale Securities [Member] | ||
Interest Receivable | $ 38,000 | $ 25,000 |
Note 4 - Marketable Securitie_3
Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Total marketable securities | $ 20,826 | $ 3,995 |
Fair Value, Inputs, Level 1 [Member] | ||
Total marketable securities | ||
Fair Value, Inputs, Level 2 [Member] | ||
Total marketable securities | 20,826 | 3,995 |
Fair Value, Inputs, Level 3 [Member] | ||
Total marketable securities | ||
US Government Agencies Debt Securities [Member] | ||
Total marketable securities | 12,827 | 1,998 |
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Total marketable securities | ||
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Total marketable securities | 12,827 | 1,998 |
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Total marketable securities | ||
Bank Certificates of Deposit [Member] | ||
Total marketable securities | 1,748 | |
Bank Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Total marketable securities | ||
Bank Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Total marketable securities | 1,748 | |
Bank Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Total marketable securities | ||
Commercial Paper and Corporate Bonds [Member] | ||
Total marketable securities | 6,251 | 1,997 |
Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Total marketable securities | ||
Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Total marketable securities | 6,251 | 1,997 |
Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Total marketable securities |
Note 5 - Amounts Receivable - A
Note 5 - Amounts Receivable - Amounts Receivable (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Research and development incentives | $ 289 | $ 793 |
Accrued interest | 38 | 17 |
Sales-based taxes receivable | 13 | |
Other | 8 | |
Total amounts receivable | $ 335 | $ 823 |
Note 6 - Deposits - Deposits (D
Note 6 - Deposits - Deposits (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Advances to vendors - current | $ 10 | $ 88 |
Note 7 - Property and Equipme_3
Note 7 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Property, plant and equipment, gross | $ 109 | $ 107 |
Less accumulated depreciation | (59) | (43) |
Property and equipment, net | 50 | 64 |
Furniture and Fixtures [Member] | ||
Property, plant and equipment, gross | 51 | 51 |
Computer Equipment [Member] | ||
Property, plant and equipment, gross | $ 58 | $ 56 |
Note 8 - Accrued Liabilities -
Note 8 - Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Accrued compensation | $ 340 | $ 419 |
Accrued clinical study costs | 211 | 433 |
Accrued research and other professional fees | 94 | 172 |
Accrued taxes and other liabilities | 13 | 52 |
Total accrued liabilities | $ 658 | $ 1,076 |
Note 9 - Operating Lease (Detai
Note 9 - Operating Lease (Details Textual) - USD ($) | 9 Months Ended | |
Sep. 30, 2020 | Jun. 30, 2020 | |
Lessee, Operating Lease, Discount Rate | 9.00% | |
Operating Lease, Cost | $ 49,000 | |
Variable Lease, Cost | $ 40,000 |
Note 9 - Operating Lease - Matu
Note 9 - Operating Lease - Maturity of Operating Lease Liability (Details) $ in Thousands | Sep. 30, 2020USD ($) |
2020 | $ 17 |
2021 | 68 |
2022 | 46 |
Total lease payments | 131 |
Less interest portion | (11) |
Present value of lease obligation | $ 120 |
Note 10 - Shareholders' Equit_2
Note 10 - Shareholders' Equity (Details Textual) - USD ($) | Aug. 10, 2020 | Feb. 13, 2020 | Mar. 31, 2020 | Jun. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 11, 2020 |
Stock Issued During Period, Shares, New Issues (in shares) | 4,600,000 | 2,125,000 | |||||
Shares Issued, Price Per Share (in dollars per share) | $ 5 | $ 4 | |||||
Proceeds from Issuance of Common Stock | $ 23,000,000 | $ 8,500,000 | $ 28,872,000 | ||||
Proceeds from Issuance of Common Stock, Net | $ 21,200,000 | $ 7,700,000 | |||||
Stock Issued During Period, Value, Stock Options Exercised | $ 16,000 | $ 75,000 | |||||
Private Placement [Member] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 7,200 | 50,000 | |||||
Stock Issued During Period, Value, Stock Options Exercised | $ 16,000 | $ 75,000 | |||||
Warrant Issued for Strategic Advisory Services [Member] | Craig-Hallum Capital Group LLC [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 10,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4 | ||||||
Warrants Issued in Private Placement [Member] | |||||||
Stock Issued During Period, Shares, Exercise of Common Stock Warrants (in shares) | 0 | 0 |
Note 10 - Shareholders' Equit_3
Note 10 - Shareholders' Equity - Shares Reserved (Details) | Sep. 30, 2020shares |
Common stock reserved for future issuance (in shares) | 2,815,067 |
Stock Options Outstanding [Member] | |
Common stock reserved for future issuance (in shares) | 1,395,399 |
Deferred Share Units [Member] | |
Common stock reserved for future issuance (in shares) | 47,237 |
The 2019 Omnibus Incentive Plan [Member] | |
Common stock reserved for future issuance (in shares) | 1,107,431 |
Common Share Purchase Warrants [Member] | |
Common stock reserved for future issuance (in shares) | 265,000 |
Note 11 - Net Loss Per Share -
Note 11 - Net Loss Per Share - Schedule of Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Net Income (Loss) Attributable to Parent, Total | $ (3,193) | $ (2,474) | $ (2,425) | $ (2,448) | $ (2,469) | $ (3,252) | $ (8,092) | $ (8,169) |
Weighted average shares outstanding—basic and diluted (in shares) | 16,689,074 | 12,006,874 | 14,652,749 | 11,981,233 | ||||
Basic and diluted net loss per share (in dollars per share) | $ (0.19) | $ (0.20) | $ (0.55) | $ (0.68) |
Note 11 - Net Loss Per Share _2
Note 11 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Employee and Non-employee Stock Options [Member] | ||||
Antidilutive Securities (in shares) | 1,395,399 | 1,251,893 | 1,395,399 | 1,251,893 |
Warrant [Member] | ||||
Antidilutive Securities (in shares) | 265,000 | 807,563 | 265,000 | 807,563 |
Deferred Share Units [Member] | ||||
Antidilutive Securities (in shares) | 47,237 | 21,183 | 47,237 | 21,183 |
Note 12 - Share-based Compens_3
Note 12 - Share-based Compensation (Details Textual) - shares | 1 Months Ended | 9 Months Ended |
Mar. 30, 2019 | Sep. 30, 2020 | |
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 2,815,067 | |
The 2019 Omnibus Incentive Plan [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 2,000,000 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 866,515 | |
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 26,054 | |
The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |
The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | Minimum [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year | |
The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | Maximum [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |
The 2019 Omnibus Incentive Plan [Member] | Nonemployee Stock Options [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 5 years | |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year | |
Stock Option Prior Plan [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 528,884 | |
The 2012 DSU Plan [Member] | ||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 21,183 | |
The 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan [Member] | ||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 1,442,636 |
Note 12 - Share-based Compens_4
Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Total share-based compensation | $ 508 | $ 451 | $ 1,337 | $ 763 |
Research and Development Expense [Member] | ||||
Total share-based compensation | 141 | 151 | 379 | 276 |
General and Administrative Expense [Member] | ||||
Total share-based compensation | $ 367 | $ 300 | $ 958 | $ 487 |
Note 12 - Share-based Compens_5
Note 12 - Share-based Compensation - Stock Option Activity (Details) - Share-based Payment Arrangement, Option [Member] - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Dec. 31, 2019 | |
Balance (in shares) | 1,220,359 | |
Balance, weighted average exercise price (in dollars per share) | $ 5.32 | |
Balance, aggregate intrinsic value | $ 301 | |
Granted (in shares) | 282,332 | |
Granted, weighted average exercise price (in dollars per share) | $ 4.77 | |
Exercised (in shares) | (7,200) | |
Exercised, weighted average exercise price (in dollars per share) | $ 2.25 | |
Expired/cancelled (in shares) | (78,147) | |
Expired / cancelled, weighted average exercise price (in dollars per share) | $ 5.10 | |
Forfeited (in shares) | (21,945) | |
Forfeited, weighted average exercise price (in dollars per share) | ||
Balance (in shares) | 1,395,399 | |
Balance, weighted average exercise price (in dollars per share) | $ 5.24 |
Note 12 - Share-based Compens_6
Note 12 - Share-based Compensation - Stock Options Outstanding (Details) | 9 Months Ended |
Sep. 30, 2020$ / sharesshares | |
Outstanding, shares (in shares) | shares | 1,395,399 |
Outstanding, weighted average remaining contractual life (Year) | 7 years 292 days |
Outstanding, weighted average exercise price (in dollars per share) | $ 5.24 |
Exercisable, shares (in shares) | shares | 887,751 |
Exercisable, weighted average remaining contractual life (Year) | 7 years 73 days |
Exercise Price Range 1 [Member] | |
Per share exercise price, lower range (in dollars per share) | $ 2 |
Per share exercise price, upper range (in dollars per share) | $ 2.99 |
Outstanding, shares (in shares) | shares | 125,700 |
Outstanding, weighted average remaining contractual life (Year) | 5 years 109 days |
Outstanding, weighted average exercise price (in dollars per share) | $ 2.28 |
Exercisable, shares (in shares) | shares | 125,700 |
Exercisable, weighted average remaining contractual life (Year) | 5 years 73 days |
Exercise Price Range 2 [Member] | |
Per share exercise price, lower range (in dollars per share) | $ 3 |
Per share exercise price, upper range (in dollars per share) | $ 3.99 |
Outstanding, shares (in shares) | shares | 97,905 |
Outstanding, weighted average remaining contractual life (Year) | 6 years 73 days |
Outstanding, weighted average exercise price (in dollars per share) | $ 3.88 |
Exercisable, shares (in shares) | shares | 97,905 |
Exercisable, weighted average remaining contractual life (Year) | 6 years 73 days |
Exercise Price Range 3 [Member] | |
Per share exercise price, lower range (in dollars per share) | $ 4 |
Per share exercise price, upper range (in dollars per share) | $ 4.99 |
Outstanding, shares (in shares) | shares | 932,744 |
Outstanding, weighted average remaining contractual life (Year) | 8 years 255 days |
Outstanding, weighted average exercise price (in dollars per share) | $ 4.56 |
Exercisable, shares (in shares) | shares | 483,716 |
Exercisable, weighted average remaining contractual life (Year) | 8 years 146 days |
Exercise Price Range 4 [Member] | |
Per share exercise price, lower range (in dollars per share) | $ 5 |
Per share exercise price, upper range (in dollars per share) | $ 10 |
Outstanding, shares (in shares) | shares | 188,900 |
Outstanding, weighted average remaining contractual life (Year) | 7 years |
Outstanding, weighted average exercise price (in dollars per share) | $ 7.84 |
Exercisable, shares (in shares) | shares | 130,280 |
Exercisable, weighted average remaining contractual life (Year) | 7 years 73 days |
Exercise Price Range 5 [Member] | |
Per share exercise price, lower range (in dollars per share) | $ 10.01 |
Per share exercise price, upper range (in dollars per share) | $ 34 |
Outstanding, shares (in shares) | shares | 50,150 |
Outstanding, weighted average remaining contractual life (Year) | 2 years 36 days |
Outstanding, weighted average exercise price (in dollars per share) | $ 18.16 |
Exercisable, shares (in shares) | shares | 50,150 |
Exercisable, weighted average remaining contractual life (Year) | 2 years 36 days |
Note 13 - Related Party Trans_2
Note 13 - Related Party Transaction (Details Textual) - Vice President [Member] - Consulting Services [Member] | 3 Months Ended | 9 Months Ended |
Sep. 30, 2020USD ($) | Sep. 30, 2020USD ($) | |
Accounts Payable, Related Parties, Current | $ 11,000 | $ 11,000 |
Research and Development Expense [Member] | ||
Related Party Transaction, Amounts of Transaction | $ 90,000 | $ 137,000 |
Note 14 - Commitments and Con_2
Note 14 - Commitments and Contingencies (Details Textual) $ in Millions | Dec. 27, 2019USD ($) |
Legalist Fund II, L.P. (Funder) [Member] | Lawsuit Against PRA Netherlands [Member] | Pending Litigation [Member] | |
Litigation Funding Agreement, Maximum Funds Received | $ 1 |